Akoya Biosciences (AKYA) Competitors

Akoya Biosciences (NASDAQ:AKYA) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Which has stronger valuation and earnings, AKYA or MASS?

Akoya Biosciences has higher revenue and earnings than 908 Devices. 908 Devices is trading at a lower price-to-earnings ratio than Akoya Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akoya Biosciences	$79.96M	0.81	-$55.37M	-$0.97	-1.33
908 Devices	$59.63M	4.46	-$72.21M	-$0.54	-13.74

Do insiders & institutionals hold more shares of AKYA or MASS?

79.4% of Akoya Biosciences shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 7.3% of Akoya Biosciences shares are owned by company insiders. Comparatively, 23.7% of 908 Devices shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is AKYA or MASS more profitable?

908 Devices has a net margin of -28.80% compared to Akoya Biosciences' net margin of -59.44%. 908 Devices' return on equity of -27.10% beat Akoya Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akoya Biosciences	-59.44%	-487.85%	-35.86%
908 Devices	-28.80%	-27.10%	-20.49%

Which has more risk & volatility, AKYA or MASS?

Akoya Biosciences has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.

Does the media prefer AKYA or MASS?

In the previous week, 908 Devices had 5 more articles in the media than Akoya Biosciences. MarketBeat recorded 6 mentions for 908 Devices and 1 mentions for Akoya Biosciences. 908 Devices' average media sentiment score of 1.34 beat Akoya Biosciences' score of 0.00 indicating that 908 Devices is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akoya Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
908 Devices	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer AKYA or MASS?

Akoya Biosciences currently has a consensus target price of $2.51, suggesting a potential upside of 94.26%. 908 Devices has a consensus target price of $5.33, suggesting a potential downside of 28.12%. Given Akoya Biosciences' higher probable upside, analysts clearly believe Akoya Biosciences is more favorable than 908 Devices.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akoya Biosciences	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

908 Devices beats Akoya Biosciences on 11 of the 16 factors compared between the two stocks.